Phase II study of pembrolizumab (MK-3475) for relapsed/refractory classical Hodgkin Lymphoma (r/r cHL): keynote-087

Phase II study of pembrolizumab (MK-3475) for relapsed/refractory classical Hodgkin Lymphoma (r/r cHL): keynote-087

Bibliographic Details
Main Authors: Chen, Robert, Armand, Phillippe, Fanale, Michelle A, Ribrag, Vincent, Zinzani, Pier Luigi, Ricart, Alejandro D, Thompson, Seth, Balakumaran, Arun, Molin, Daniel, Shipp, Margaret A, Moskowitz, Craig H
Format: Online
Language:English
Published: BioMed Central 2015
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645991/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645991/

Similar Items